Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118080 | 0.81 | CYP2A6 (0.59) | CYP2A6KEAP1NFE2L2MAPTLMNA | |
| SCHEMBL4153169 | 0.79 | MAPT (0.42) | MAPTLMNAIDO1CA2TP53 | |
| SCHEMBL13737283 | 0.78 | CYP2A6 (0.50) | CYP2A6MAPTCA2TP53CYP17A1 | |
| SCHEMBL18935935 | 0.78 | CYP17A1 (0.36) | CYP2A6CYP17A1 | |
| SCHEMBL7917778 | 0.76 | CYP2A6 (0.62) | CYP2A6KEAP1NFE2L2MAPTLMNA | |
| SCHEMBL29017448 | 0.74 | CYP2A6 (0.64) | CYP2A6KEAP1NFE2L2MAPTLMNA | |
| SCHEMBL30492726 | 0.72 | CYP2A6 (0.45) | CYP2A6MAPTSMN1; SMN2CA2TP53 | |
| SCHEMBL3682441 | 0.72 | CYP2A6 (0.62) | CYP2A6KEAP1NFE2L2MAPTLMNA | |
| SCHEMBL9103428 | 0.72 | CYP2A6 (0.45) | CYP2A6MAPTSMN1; SMN2CA2TP53 | |
| SCHEMBL10411294 | 0.71 | CYP2A6 (0.60) | CYP2A6KEAP1NFE2L2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | CYP2A6 345/4885KEAP1 2456/4885NFE2L2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.